Effectiveness of Trastuzumab for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in a Real-Life Setting: One Decade of Experience Under National Treatment Coverage Regulations

PURPOSE: Trastuzumab has shown an overall survival (OS) benefit in patients with human epidermal growth factor receptor 2 (HER2)–positive breast cancer (BC), in both the adjuvant and the metastatic setting. We assessed the effectiveness of trastuzumab in patients treated in daily practice according...

Descripción completa

Detalles Bibliográficos
Autores principales: Camejo, Natalia, Castillo, Cecilia, Alonso, Rafael, Correa, Fernando, Rivero, Emiliano, Mezquita, Camila, Rosich, Agustin, Dellacasa, Fiamma, Silveira, Luciana, Delgado, Lucía
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2020
Materias:
Original Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7051800/
https://www.ncbi.nlm.nih.gov/pubmed/32045546
http://dx.doi.org/10.1200/JGO.19.00299

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7051800/
https://www.ncbi.nlm.nih.gov/pubmed/32045546
http://dx.doi.org/10.1200/JGO.19.00299

Ejemplares similares